US/UK/Canada

Share

Links

Quotes

Genetic Analysis GA-map® enables cost-efficient and reliable mapping and profiling of gut microbiota via In Vitro Diagnostics (IVD) testing. Genetic Analysis is currently the only company globally that offers a patented and CE-marked standardized testing platform for microbiome analysis, the GA-map® Dysbiosis Test. GA has initiated an ambitious growth plan to rapidly grow the business over the next few years in the EU and US. We have proven our existing business model to molecular labs, and the Company is now ready, with the CE-marked GA-map®, to be commercialized in the current market for microbiota testing as well as to enter the market for companion diagnostics, where the test will be performed in combination with microbiota altering drugs. The growth plan will expand the commercialization through carefully selected distributors for vast expansion and strategic direct sales of the current product portfolio within Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Based on the competitive advantages that a standardized diagnostic platform will have in the microbiota field, compared to the current research-based tools, and the huge number of potential patients, we assess that the market for GA’s technology is significant.
Ronny Hermansen, CEO
GA accomplished essential milestones during the period by being granted patents in US, Japan, India and the EU. In June, we successfully completed the next generation of the GA-map® Dysbiosis Test with a CE mark. The next generation includes a built-in bacteria functionality reporting algorithm that will further reduce run-time for the lab. We expanded our distribution network with Eagle Bioscience in the US and reached a significant agreement with a lab chain in Germany to sell the GA-map® platform installation package. Finally – GA, together with the Norwegian University of Life Sciences, is developing the world’s first complete database of reference genomes, HumGut, a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut. Mapping and unlocking the genes present in a healthy gut is instrumental for developing new diagnostics and better treatment regimes. We will actively use this powerful search engine and database to identify novel gut signatures which we can plug onto our GA map® technology platform to develop new innovative diagnostic markers within the microbiome field.
Ronny Hermansen, CEO
Pick a time period -
Tags ( Active)

Genetic Analysis AS: Publication of Half-year report 2024

OSLO, NORWAY – 30 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for H1, and april - June 2024. The Half-year report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“I am happy to see that GA continues to attract new Lab customers to use the GA-map® diagnostic system and that we are increasing our lead pipeline. Thus, our core business consisting of reagent kit sales increased 135 percent in Q2 compared to Q2

Genetic Analysis directed issue to major shareholders has now been registered with the Norwegian Register of Business Enterprises

Genetic Analysis AS' (“GA” or the “Company”) directed issue to current major shareholders and certain members of the board of directors and management has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).On July 1 and July 17, 2024, GA carried out the directed issue that provided the Company with NOK 5.42 million by issuance of 7,225,916 new shares, before issue costs. The direct Issue has now been registered with the Norwegian Register of Business Enterprises. After this, the Company's new registered share capital is NOK 29,629,962.60

Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology

OSLO, NORWAY – August 8, 2024: Microbiome DX company Genetic Analysis AS ("GA") announces the completion and launch of a consumer microbiome testing platform in partnership with Prokarimi AS ("Prokarimi"). This strategic initiative marks GA’s presence in the Nordic consumer market via its partner, offering an accessible and user-friendly microbiome gut health testing service.As communicated in December 2023, GA and Comono AS established a Joint Venture—Prokarimi—to develop a digital gut health testing platform targeting the consumer market, with an initial launch planned for Q2 2024. Today,

Genetic Analysis AS: Minutes from the Extraordinary General Meeting 17 July 2024

Oslo, Norway, July 17, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) held an Extraordinary General Meeting today, July 17[th], at 09:00 hours (CET) on the Company's premises in Ulvenveien 80, Oslo. All items on the agenda were approved as proposed.The agenda for the meeting was as follows: Opening of the meeting by the chairman of the board The general meeting was opened by chairman of the board, Jethro Holter, who took record of attending shareholders as set out in Appendix 1 to the minutes. In total, 12,750,572 of the Company's 42,155,355 shares were represented,

Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises

OSLO, NORWAY - July 15, 2024: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that the direct issue which was announced in a press release on the 01.07.2024 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).GA announced that a direct issue was completed on the 01.07.2024 This provided the Company with approximately NOK 4.97 million by issuance of 6 625 916 new shares, before issue costs. The direct issue has now been registered with the Norwegian Register of Business Enterprises. After this, the Company'

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 04 July 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS on Wednesday 03.07.2024 bought 45.500 GEAN shares at an average price of 1,09 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 840.200 shares and 516.668 options.

Genetic Analysis AS: Notice of Extraordinary General Meeting 2024

Oslo, Norway, July 3, 2024 - Notice is hereby served that an extraordinary general meeting of Genetic Analysis AS (the "Company") will be held on Wednesday 17 July 2024 at 09:00 hours in the Company's premises in Ulvenveien 80, Oslo.Shareholders are encouraged to submit a proxy with voting instructions prior to the general meeting, see Appendix 2. Shareholders that still wish to participate in the general meeting are encouraged to notify the Company as stipulated in Appendix 1.   Agenda:   1. Opening of the meeting   2. Election of a chairperson and a person to co-sign

Genetic Analysis: Flagging notification

OSLO, NORWAY - July 1, 2024: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that an existing shareholder, Muen Invest AS, crosses the flagging threshold as a result of the recently announced directed share issue.Muen Invest AS currently holds 2.101.794 shares, corresponding to 4,98% of the votes and capital in Genetic Analysis AS. Through the recently communicated directed share issue, communicated on July 1, 2024, Muen Invest AS has been allocated 1,133,334 shares. When the directed share issue is registered, Muen Invest AS will own 3,235,128 shares,

Genetic Analysis announces placement of a directed share issue of approximately NOK 4.97 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. Genetic Analysis AS (“GA” or the “Company”) is pleased to announce that it has successfully placed a directed issue and on basis of commitments

Genetic Analysis: Awarded important EU patent covering a companion diagnostic method for optimising IBS interventions

OSLO, NORWAY – 13 June 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today the grant of an important patent (EP3526340) by the European Patent Office (EPO) entitled “A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT”. The invention covered provides a diagnostic method to be used to determine the likelihood that a patient with Irritable Bowel Syndrome (IBS) will respond to treatment with a low-FODMAP diet or Faecal Microbiota Transplant (FMT). In 2021, the company

Genetic Analysis AS: CFO resigns to pursue other opportunities

OSLO, NORWAY – 06 June 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that Eilert Aamodt has decided to resign as CFO to take on a new position in another company and industry. He will remain in his current role until the end of August 2024, ensuring a smooth and efficient transition for GA. Aamodt has been with GA since February 2021, and GA has initiated a process to recruit his replacement.Ronny Hermansen, CEO of Genetic Analysis, comments:“I would like to thank Eilert for his valuable contribution to GA over the years, where he has established a

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 3 June 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the board of directors has bought GEAN-shares.Jethro Holter, Chairperson of Genetic Analysis AS, has on Friday 31.05.2024 bought 13.000 GEAN shares at an average price of 0,70 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Jethro Holter owns 30.898 shares in the Company.

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 31 May 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the board of directors has bought GEAN-shares.Jethro Holter, Chairperson of Genetic Analysis AS, has on Wednesday 29.05.2024 and Thursday 30.05.2024 bought in total 17.898 GEAN shares at an average price of 0,66 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Jethro Holter owns 17.898 shares in the Company.

Genetic Analysis AS: Publication of Q1 report January – March 2024

OSLO, NORWAY – May 29, 2024: Today, Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for the period January 1 – March 31, 2024. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“During Q1 2024, GA has continued to onboard new laboratory customers by implementing the GA-map® assay on their instrument. A key objective for GA is technology implementation in laboratories since this generates recurring reagent

Minutes from the Annual General Meeting 2024 in Genetic Analysis AS

Oslo, Norway, May 15, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) held its Annual General Meeting yesterday, May 14[th], at 15:00 hours (CET) on the Company's premises in Ulvenveien 80, Oslo. All items on the agenda were approved as proposed.The agenda for the meeting was as follows: 1. Election of a chairperson and a person to co-sign the minutes Chairperson Per Matsson was elected to chair the general meeting, and Jethro Holter was elected to co-sign the minutes with the chairperson. 2. Approval of the annual accounts and directors' report of Genetic Analysis AS for

Genetic Analysis AS: Notice of Annual General Meeting 2024

Oslo, Norway, April 24, 2024 - Notice is hereby served that the annual general meeting of Genetic Analysis AS (the "Company") will be held on Tuesday 14 May 2024 at 15:00 hours in the Company's premises in Ulvenveien 80, Oslo.Shareholders are encouraged to submit a proxy with voting instructions prior to the general meeting, see Appendix 2. Shareholders that still wish to participate in the general meeting are encouraged to notify the Company as stipulated in Appendix 1. Agenda: 1. Opening of the meeting 2. Election of a chairperson and a person to co-sign the minutes The

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 19 April 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS on Thursday 17.04.2024 bought 107.751 GEAN shares at an average price of 0,65 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 794.700 shares and 516.668 options.

Genetic Analysis AS: Publication of Annual Report 2023

Oslo, Norway, April 18, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) hereby publishes the Annual Report for the financial year of 2023. The Annual Report is available as an attached file to this release and on the Company's website (www.genetic-analysis.com).The company's auditor has stated in his auditor’s report on page 1 that there is material uncertainty related to going concern. The wording is reproduced below in full: Material Uncertainty Related to Going Concern“We draw attention to Note 25 in the financial statements, which indicates that the Company projects that

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 14 March 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.Christina Casén, SVP Clinical & Medical Affairs of Genetic Analysis AS, has yesterday Wednesday 13.03.2024 bought 16.500 GEAN shares at an average price of 0,61 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Christina Casén owns 176.989 shares and 210.000 options.

Genetic Analysis AS: Mandatory notification of trade – Primary Insider

OSLO, NORWAY – 11 March 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS on Friday 08.03.2024 bought 104.697 GEAN shares at an average price of 0,60 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 686.949 shares and 566.669 options.

Year-end report January – December 2023

Oslo, Norway, February 29, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) hereby publishes the year-end report for the period 1 January - December 31, 2023. The year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:"2023 was a year when we increased our presence in the microbiome testing market and took a leap forward in our commercialization journey. We have further developed and enhanced our GA-map® platform, entered into new distribution agreements, and

Genetic Analysis AS: Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit

Oslo, Norway, November 26, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) is proud to announce that its GA-map® Sample Collection Kit has obtained CE-IVD marking under the In Vitro Diagnostic Regulation (EU) 2017/746. The GA-map® Sample Collection Kit is a device that simplifies the sample collection process, allowing easy and user-friendly collection of fecal samples at home, without compromising the quality and integrity of the test results. The kit inactivates bacteria and viruses and has documented sample preservation at room temperature for up to four weeks and at -20°C for up

Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises

Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on December 22, 2023 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).During the period December 11 – December 22, 2023, GA carried out the Subsequent Offering that provided the Company with approximately NOK 3.1 million by issuance of 3,958,036 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe